UARK 2003-25: A Phase I/II Open Label Study of IV Busulfan (Busulfex) in Multiple Myeloma Patients Older Than 65 Years of Age or With Renal Insufficiency.

Trial Profile

UARK 2003-25: A Phase I/II Open Label Study of IV Busulfan (Busulfex) in Multiple Myeloma Patients Older Than 65 Years of Age or With Renal Insufficiency.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Busulfan (Primary) ; Melphalan
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 04 Mar 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 29 Jun 2010 Actual patient number is 14 as reported by ClinicalTrials.gov.
    • 29 Jun 2010 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top